QLGN Qualigen Corp: רווח למניה לשנה מתגלגלת

Qualigen Therapeutics (QLGN) possesses significant scientific authority in the development of small molecules and precision test systems. The company is advancing its oncology pipeline through partnerships with leading academic centers. Management is currently optimizing expenses, focusing capital on priority drug candidates. The current value is 32.80, which is clearly demonstrated by the 12-month YoY EPS growth chart.
פילוחי מדדים פיננסיים ומדדי שוק עבור Qualigen Corp (QLGN)

This indicator measures the annual dynamics of net income per share using a TTM rolling window to neutralize seasonality. Analyzing the EPS YoY TTM shift allows for the separation of one-time gains from sustainable capitalization growth. The metric reveals the actual efficiency of value generation. For Qualigen Therapeutics (QLGN), this is a critical marker for controlling operating expenses. A positive trend would confirm the success of the restructuring and a reduction in the capital burn rate.